You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 13, 2024

LUMIGAN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Lumigan patents expire, and what generic alternatives are available?

Lumigan is a drug marketed by Abbvie and is included in two NDAs. There are twelve patents protecting this drug and two Paragraph IV challenges.

This drug has thirty-four patent family members in twenty-two countries.

The generic ingredient in LUMIGAN is bimatoprost. There are twelve drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lumigan

A generic version of LUMIGAN was approved as bimatoprost by APOTEX on December 1st, 2014.

  Try a Trial

Drug patent expirations by year for LUMIGAN
Drug Prices for LUMIGAN

See drug prices for LUMIGAN

Drug Sales Revenue Trends for LUMIGAN

See drug sales revenues for LUMIGAN

Recent Clinical Trials for LUMIGAN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Laboratoires TheaPhase 1
Amneal Pharmaceuticals, LLCPhase 3
Mankind Pharma LimitedPhase 3

See all LUMIGAN clinical trials

Pharmacology for LUMIGAN
Paragraph IV (Patent) Challenges for LUMIGAN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
LUMIGAN Ophthalmic Solution bimatoprost 0.01% 022184 1 2011-04-05
LUMIGAN Ophthalmic Solution bimatoprost 0.03% 021275 1 2008-12-22

US Patents and Regulatory Information for LUMIGAN

LUMIGAN is protected by thirteen US patents.

Patents protecting LUMIGAN

Enhanced bimatoprost ophthalmic solution
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Enhanced bimatoprost ophthalmic solution
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Enhanced bimatoprost ophthalmic solution
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION

Enhanced bimatoprost ophthalmic solution
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD OF LOWERING INTRAOCULAR PRESSURE IN A PATIENT WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

Enhanced bimatoprost ophthalmic solution
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF TREATING GLAUCOMA IN A PATIENT

Enhanced bimatoprost ophthalmic solution
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION

Enhanced bimatoprost ophthalmic solution
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION

Enhanced bimatoprost ophthalmic solution
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD OF REDUCING INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

Enhanced bimatoprost ophthalmic solution
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD OF LOWERING INTRAOCULAR PRESSURE

Enhanced bimatoprost ophthalmic solution
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Enhanced bimatoprost ophthalmic solution
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Enhanced bimatoprost ophthalmic solution
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD OF LOWERING INTRAOCULAR PRESSURE

Enhanced bimatoprost ophthalmic solution
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF TREATING GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbvie LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Abbvie LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Abbvie LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Abbvie LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbvie LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 021275-001 Mar 16, 2001 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LUMIGAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 ⤷  Try a Trial ⤷  Try a Trial
Abbvie LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 021275-001 Mar 16, 2001 ⤷  Try a Trial ⤷  Try a Trial
Abbvie LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 ⤷  Try a Trial ⤷  Try a Trial
Abbvie LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 ⤷  Try a Trial ⤷  Try a Trial
Abbvie LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 021275-001 Mar 16, 2001 ⤷  Try a Trial ⤷  Try a Trial
Abbvie LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 021275-001 Mar 16, 2001 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for LUMIGAN

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
AbbVie Deutschland GmbH & Co. KG Lumigan bimatoprost EMEA/H/C/000391
Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers).,
Authorised no no no 2002-03-08
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for LUMIGAN

See the table below for patents covering LUMIGAN around the world.

Country Patent Number Title Estimated Expiration
Austria E431152 ⤷  Try a Trial
Argentina 055050 COMPOSICION FARMACEUTICA QUE COMPRENDE N-ETIL-9A, 11A, 15S- TRIHIDOXI-17-FENIL-18,19,20-TRINOR-PROSTA -5Z, 13E- DIEN-1-AMIDA (BIMATOPROST) Y CLORURO DE BENZALCONIO, Y USO DE ESTOS COMPUESTOS PAR LA PREPARACION DE LA MISMA ⤷  Try a Trial
Germany 69613693 ⤷  Try a Trial
Canada 2585691 SOLUTION OPHTALMIQUE DE BIMATOPROST AMELIOREE (ENHANCED BIMATOPROST OPHTHALMIC SOLUTION) ⤷  Try a Trial
Norway 337190 ⤷  Try a Trial
Australia 693698 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for LUMIGAN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0660716 02C0033 France ⤷  Try a Trial PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION:
0660716 C300099 Netherlands ⤷  Try a Trial PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308
0660716 SPC/GB02/035 United Kingdom ⤷  Try a Trial PRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308
0660716 90957 Luxembourg ⤷  Try a Trial
0660716 CA 2002 00020 Denmark ⤷  Try a Trial
0660716 SPC023/2002 Ireland ⤷  Try a Trial SPC023/2002: 20040929, EXPIRES: 20170307
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.